Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities.
Jiang YZ, Ma D, Jin X, Xiao Y, Yu Y, Shi J, Zhou YF, Fu T, Lin CJ, Dai LJ, Liu CL, Zhao S, Su GH, Hou W, Liu Y, Chen Q, Yang J, Zhang N, Zhang WJ, Liu W, Ge W, Yang WT, You C, Gu Y, Kaklamani V, Bertucci F, Verschraegen C, Daemen A, Shah NM, Wang T, Guo T, Shi L, Perou CM, Zheng Y, Huang W, Shao ZM. Jiang YZ, et al. Among authors: verschraegen c. Nat Cancer. 2024 Apr;5(4):673-690. doi: 10.1038/s43018-024-00725-0. Epub 2024 Feb 12. Nat Cancer. 2024. PMID: 38347143
Clinical markers of immunotherapy outcomes in advanced sarcoma.
Husain M, Quiroga D, Kim HG, Lenobel S, Xu M, Iwenofu H, Chen JL, Verschraegen C, Liebner D, Tinoco G. Husain M, et al. Among authors: verschraegen c. BMC Cancer. 2023 Apr 7;23(1):326. doi: 10.1186/s12885-023-10758-w. BMC Cancer. 2023. PMID: 37029351 Free PMC article.
Emerging Trends in Immunotherapy for Adult Sarcomas.
Husain M, Chen L, Liebner D, Beane J, Rubinstein M, Pollock R, Verschraegen C, Tinoco G. Husain M, et al. Among authors: verschraegen c. Oncologist. 2023 May 8;28(5):e233-e241. doi: 10.1093/oncolo/oyad052. Oncologist. 2023. PMID: 36905579 Free PMC article.
Quality of life and patient-reported toxicities in patients with advanced Merkel cell carcinoma treated with combined nivolumab and ipilimumab with or without stereotactic body radiation therapy.
Hoogland AI, Brohl AS, Small BJ, Michael L, Wuthrick E, Eroglu Z, Blakaj D, Verschraegen C, Khushalani NI, Jim HSL, Kim S. Hoogland AI, et al. Among authors: verschraegen c. Cancer Med. 2024 Jul;13(14):e7464. doi: 10.1002/cam4.7464. Cancer Med. 2024. PMID: 39021272 Free PMC article. Clinical Trial.
Inhibition of Bruton's tyrosine kinase with PD-1 blockade modulates T cell activation in solid tumors.
Schwarz E, Benner B, Wesolowski R, Quiroga D, Good L, Sun SH, Savardekar H, Li J, Jung KJ, Duggan MC, Lapurga G, Shaffer J, Scarberry L, Konda B, Verschraegen C, Kendra K, Shah M, Rupert R, Monk P, Shah HA, Noonan AM, Bixel K, Hays J, Wei L, Pan X, Behbehani G, Hu Y, Elemento O, Chung D, Xin G, Blaser BW, Carson WE 3rd. Schwarz E, et al. Among authors: verschraegen c. JCI Insight. 2024 Nov 8;9(21):e169927. doi: 10.1172/jci.insight.169927. JCI Insight. 2024. PMID: 39513363 Free PMC article. Clinical Trial.
Hedgehog pathway inhibitors for locally advanced and metastatic basal cell carcinoma: A real-world single-center retrospective review.
Patel S, Armbruster H, Pardo G, Archambeau B, Kim NH, Jeter J, Wu R, Kendra K, Contreras CM, Spaccarelli N, Dulmage B, Pootrakul L, Carr DR, Verschraegen C. Patel S, et al. Among authors: verschraegen c. PLoS One. 2024 Apr 30;19(4):e0297531. doi: 10.1371/journal.pone.0297531. eCollection 2024. PLoS One. 2024. PMID: 38687774 Free PMC article.
216 results